Share Twitter LinkedIn Facebook Email Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity.
SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers Gastrointestinal 8 Mins Read